Eli Lilly Anticipates Approval for Orforglipron Weight-Loss Pill in Early 2026

Jan 13, 2025, 06:07 PM

Eli Lilly & Co. is anticipating regulatory approval for its experimental weight-loss pill, orforglipron, as early as early 2026, according to CEO Dave Ricks. Ricks, speaking at the JPMorgan Healthcare Conference in San Francisco, indicated that data on the pill is expected by mid-2025. He highlighted that the oral form of the drug would be more convenient for patients and easier to manufacture at a large scale compared to the company's current injectable weight-loss drugs, which have faced supply shortages due to production constraints.